A Study for Patients With Complicated Skin and Skin Structure Infections (SIMPLIFI)

T

Targanta Therapeutics Corporation

Status and phase

Completed
Phase 2

Conditions

Cellulitis
Streptococcal Infections
Staphylococcal Skin Infections
Wounds and Injuries
Abscess

Treatments

Drug: oritavancin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00514527
TAR-ORI-SD001

Details and patient eligibility

About

Two Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment of complicated skin and skin structure infections (cSSSI) have been completed. The pharmacokinetic profile of oritavancin in humans suggests that oritavancin has the potential to be used safely and effectively when given either as a single dose or as an infrequent dose for cSSSI. Data from animals support this theory. SIMPLIFI has been designed to evaluate the efficacy and safety of either a single dose of oritavancin or an infrequent dose of oritavancin (First dose on Day one with an option for a second dose on Day five) compared to the previously studied dosing regimen of 200mg oritavancin given once daily for 3 to 7 days.

Enrollment

294 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Complicated skin and skin structure infection, presumed or proven to be caused by gram-positive pathogen(s).
  • Patients, ages 18 years and older, must not be below normal body weight or morbidly obese.
  • Female patients must not be pregnant at time of enrollment and must agree to a reliable method of birth control during the study and for 6 months following the last dose of study drug.

Exclusion Criteria:

Patients:

  • with a condition which would prevent performing protocol safety and efficacy assessments.
  • who have received antibiotics for more than 24 hours within the last 3 days.
  • with an infection involving deep tissues or unlikely to be caused by gram positive bacteria
  • who are nursing and will not stop nursing for at least 6 months
  • with a prior allergic reaction to glycopeptides (e.g. vancomycin)

with any of the following:

  • toxic shock syndrome or toxic-like syndrome
  • presumed or proven infection caused by Clostridium species
  • bone infections
  • ischemic or gangrenous ulcers or wounds
  • infections caused only by gram-negative bacteria
  • infection of an artificial joint that cannot be removed
  • infection of the scrotum, perineum or perianal region
  • infection of a severe burn wound
  • severe ear infection involving bone and/or cartilage
  • infection following injury in water possibly containing Vibrio species or following a history of eating raw oysters within 1 week prior to disease onset

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

294 participants in 3 patient groups

1
Experimental group
Treatment:
Drug: oritavancin
2
Experimental group
Treatment:
Drug: oritavancin
3
Experimental group
Treatment:
Drug: oritavancin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

Ā© Copyright 2024 Veeva Systems